Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial

JTO Clinical and Research Reports 2026 Open access

Read full text
Authors: Nicolas Girard, Jonathan Goldman, Shun Lu, Jair Bar, Hidehito Horinouchi, Nathalie Daaboul, Chunling Liu, İrfan Çiçin, Nuran Katgı, Alona Zer, Tudor Ciuleanu, Niels Reinmuth
+15 more David Planchard, Se-Hoon Lee, Aaron S. Mansfield, Mor Moskovitz, Shobhit Baijal, Christina S. Baik, John Hrom, Rebecca S. Heist, Ozan Yazici, Mukesh Verma, Deise Uema, Shilpen Patel, Summer Xia, Christine K. Ratajczak, D. Ross Camidge
DOI: 10.1016/j.jtocrr.2026.100988
Cited by: 2
References: 14

Abstract

Introduction: wild-type, nonsquamous NSCLC. We present updated outcomes with approximately 6 months longer follow-up and explore the impact of previous therapies. Methods: Patients (≥18 y; had previous therapy including ≤1 chemotherapy) received 1.9 mg/kg Teliso-V every 2 weeks. c-Met protein overexpression (clinical trial assay for MET [SP44] [Roche]) was defined as greater than or equal to 25% tumor cells with 3+ staining intensity (c-Met high: ≥50% 3+; c-Met intermediate: 25 to

Fields of Study & Subjects

HER2/EGFR in Cancer Research Lung Cancer Treatments and Mutations Protease and Inhibitor Mechanisms

Publication details

Journal / source
JTO Clinical and Research Reports
Publisher
Elsevier BV
Volume
7
Issue
7
Pages
100988–100988
Publication date
16 March 2026
Language
EN